Improving care provision for lymphoma long-term survivors
The progressive improvement of lymphoma therapies has led to a significant prolongation of patient survival and life expectancy. However, lymphoma survivors are at high risk of experiencing a range of early and late adverse effects associated with the extent of treatment exposure. Among these, second malignancies and cardiopulmonary diseases may be fatal, whereas neuro-cognitive dysfunctions, endocrinopathies, muscle atrophy and persistent fatigue can affect patient quality of life even for decades after treatment.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Sabino Ciavarella, Carla Minoia, Angela Maria Quinto, Stefano Oliva, Santa Carbonara, Claudia Cormio, Maria Christina Cox, Elena Bravo, Filippo Santoro, Mariarosaria Napolitano, Michele Spina, Giacomo Loseto, Attilio Guarini Tags: Review Article Source Type: research
More News: Brain | Cancer & Oncology | Cardiology | Heart | Hematology | Leukemia | Lymphoma | Myeloma | Neurology